Danaher Corporation (DHR) Stock: Price, Forecast & Analyst Target
Danaher Corporation (DHR) — MoonshotScore 71/100 (Strong band), calculated Nov 18, 2026. Price $227.56 (-0.45%), as of the Nov 19, 2026 trading session; market cap $160B. Expected results Jan 27, 2027.
Educational signal · not a buy or sell recommendation · How to read this
Danaher Corporation · DHR · NYSE · Healthcare · Medical - Diagnostics & Research
Research dated 2026-09-12: Danaher sells laboratory, bioprocessing, diagnostic and applied-analysis systems, then supplies many of the reagents, consumables and services those workflows continue to require. Revenue has resumed growth, but the case now depends on whether that recovery can produce durable operating leverage while substantial debt remains ahead of liquid resources.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · Danaher (DHR)
StrongWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
High quality, but a full valuation; the market is already moving on it. Business Quality: Elite; Financial Safety: Okay; Valuation: Full; Growth Durability: Flat; Momentum: Surging.
- EPS beat 0 of the last 4 reports
- expected results Jan 27, 2027
- Altman Z 3.72 · Piotroski F 7
Helping: business quality, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 70 | Strong | |
| 70 | Strong | |
| 70 | Strong | |
| 70 | Strong | |
| 71 | Strong | |
| 71 | Strong |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $227.56 | |
| Change on the day | -0.45% | |
| 52-week range | $160.93–$242.80 | |
| Market capitalisation | $160B | — |
| Price / earnings (trailing) | 36.89 | |
| Shares traded on the day | 4.06M | |
| Beta (volatility vs the S&P 500) | 0.8 |
Why Danaher scores 71
Share price, last 12 months +9.0%
$215.79 $235.31
What the price assumes
12.1% a year of free-cash-flow growth for ten years is what a $165.55B market value ( snapshot) asks for.
The price already assumes faster growth than the last 5 years delivered. Anything short of an acceleration leaves room to disappoint. It also runs ahead of the analysts' revenue path.
Reverse discounted cash flow: 10% discount rate, 3% growth after year ten, starting from trailing twelve months free cash flow of $5.73B. Inputs: FMP statements, estimates and quote.
How the stock reacts to earnings
EPS beat in 11 of the last 12 reports (2024–2026); the stock still fell the next session after 4 of those beats. Average first-session move: 6.0% either way.
- +2.6%Jan ’24
- +6.1%Apr ’24
- +5.9%Jul ’24
- -5.9%Oct ’24
- -10.0%Jan ’25
- +6.1%Apr ’25
- +5.2%Jul ’25
- +4.7%Oct ’25
- -6.8%Jan ’26
- -5.9%Apr ’26
- -10.9%Jul ’26
- +2.5%Oct ’26
Every report, with revenue and five-session moves
| Report | EPS | Revenue | Next session | 5 sessions |
|---|---|---|---|---|
| Beat | In line | +2.5% | +4.4% | |
| Beat | Beat | -10.9% | -1.0% | |
| Beat | In line | -5.9% | -8.5% | |
| Beat | In line | -6.8% | -6.9% | |
| Beat | In line | +4.7% | +4.1% | |
| Beat | Beat | +5.2% | +10.0% | |
| Beat | Beat | +6.1% | +7.6% | |
| In line | Beat | -10.0% | -14.4% | |
| Beat | Beat | -5.9% | -10.8% | |
| Beat | Beat | +5.9% | +9.7% | |
| Beat | Beat | +6.1% | +4.5% | |
| Beat | Miss | +2.6% | +6.1% |
Beats have usually been rewarded — 7 of 11 drew a higher close the next session.
Our track record on this stock
Since the score went from 65 to 71 while the share price moved +5.8% through .
| Date | Band | 3 months | 6 months | Call |
|---|---|---|---|---|
| Fair → Strong | — | — | — | |
| Strong → Fair | — | — | — | |
| Fair → Strong | — | — | — |
None of the 3 band changes we have recorded has been graded yet; we grade each band change three months after it happens.
The crowd against our signals
- Analysts: 72% of 43 rate it a buy; the average target sits +4.9% from the price of $227.56.
- Last 90 days: 11 rating actions, every one a reaffirmation.
- Our signals: Strong band; strongest pillar Momentum (87), weakest Growth Durability (45).
Here we and the crowd agree.
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
How to read these dates
Estimated dates can change.
Other perspectives
Council score for Danaher (DHR): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 16, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation
Read on: Nov 19, 2026
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
The Munger lens reads the current price as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Danaher (DHR), and what does it report?
Short answer · as of
Danaher is not simply a medical-device manufacturer: its portfolio spans research instruments, bioprocess technologies, clinical diagnostics, water analysis and packaging-quality tools. Customers range from drug developers and research institutions to hospitals, laboratories and industrial operators, so reported revenue combines capital equipment with recurring reagents, consumables, software and service demand.
Research dated 2026-09-12.
The recurring category supplies most revenue, making utilization of Danaher-supported workflows as important as new instrument purchases.
What do the latest results show for Danaher (DHR)?
Research dated 2026-09-12.
Latest revenue rose from both the preceding period and the comparable prior period, while reported earnings exceeded expectations and revenue also cleared consensus. Operating profit nevertheless declined: gross profit improved only slightly from the preceding period as selling and administrative expense and research spending increased, leaving less of the revenue gain to reach the bottom line. Operating cash flow strengthened, providing a cleaner sign of financial momentum than earnings alone.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | Not available | Not available | Not available | Not available |
| Jun 30, 2026 | Not available | Not available | Not available | Not available |
| Mar 31, 2026 | Not available | Not available | Not available | Not available |
| Dec 31, 2025 | Not available | Not available | Not available | Not available |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $6.55B Oct 21, 2026
- Latest report · revenue estimate
- $6.56B Oct 21, 2026
- Latest report · revenue vs estimate
- Below estimate Oct 21, 2026
- Latest report · EPS vs estimate
- Above estimate Oct 21, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Oct 21, 2026 | $6.55B | $6.56B | $2.1100 | $1.9200 |
| Jul 21, 2026 | $6.26B | $6.12B | $1.9400 | $1.8500 |
| Apr 21, 2026 | $5.95B | $5.98B | $2.0600 | $1.9400 |
| Jan 28, 2026 | $6.84B | $6.81B | $2.2300 | $2.1600 |
How to read these figures
Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Sep 2025 | $0 | $0 | — |
| Q4 FY2025 | $0 | $0 | — |
| Q1 FY2026 | $0 | $0 | — |
| Q2 FY2026 | $0 | $0 | — |
What are the financial strengths and risks for Danaher (DHR)?
Short answer
Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.
Research dated 2026-09-12.
Operating cash flow has exceeded capital expenditure throughout the displayed history, giving Danaher meaningful internally generated funding. Liquidity covers near-term obligations, but debt materially exceeds cash and investments, so sustained cash conversion matters more than the headline cash balance. The longer-running caution is that annual revenue stabilized before returning to growth while net income continued to recede; weaker laboratory, bioprocessing or diagnostic activity could pressure both instrument demand and the recurring consumables attached to those workflows.
Data-derived red flags
- Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
- Rich valuation — a P/E of 36.89 runs well above the Healthcare sector’s ~21.70x, leaving little room for a miss.
What should you watch next at Danaher (DHR)?
Short answer · as of
The next earnings report is expected on Jan 27, 2027.
Research dated 2026-09-12.
Danaher’s scheduled earnings release needs to be read across revenue, gross profit and operating expense together: another sales increase would be less persuasive if operating profit again moved the other way. Cash conversion, capital spending and the recent decline in cash and short-term investments will show whether growth is rebuilding financial flexibility or merely absorbing it. Consensus assumes continued expansion across the forecast horizon, so recurring revenue and demand from biopharmaceutical, research and diagnostic customers are the operating checks behind that expectation.
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
Checked against the records this page reads, on the dates shown above.
How does Danaher compare with its peers?
Short answer
Danaher's score ranks tied for 10th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-12.
Unlike a focused diagnostics or laboratory-instrument business, Danaher combines life-science research, bioprocessing, clinical testing and applied industrial analysis within one portfolio. Its economic distinction is the pairing of sophisticated systems with reagents, consumables, software and services used after placement; the recurring revenue category is far larger than the nonrecurring category. That mix spreads demand across laboratories, drug manufacturers, hospitals and industrial customers, while leaving performance tied to activity across several specialized workflows rather than a single product cycle.
| Company | Price | Market value | Score |
|---|---|---|---|
| $689.65 Nov 19, 2026 | $54.3B | 96 5-pillar Nov 18, 2026 | |
| $420.95 Nov 18, 2026 | $146B | 94 5-pillar Nov 18, 2026 | |
| $1705.66 Nov 19, 2026 | $33.9B | 93 5-pillar Nov 18, 2026 | |
| $47.12 Nov 18, 2026 | $113B | 87 5-pillar Nov 18, 2026 | |
| $443.89 Nov 18, 2026 | $240B | 84 5-pillar Nov 18, 2026 | |
| $210.01 Nov 18, 2026 | $31.8B | 84 5-pillar Nov 18, 2026 | |
| $175.34 Nov 19, 2026 | $49.4B | 83 5-pillar Nov 18, 2026 | |
| $258.99 Nov 19, 2026 | $28.5B | 74 5-pillar Nov 18, 2026 | |
| $168.98 Nov 18, 2026 | $210B | 72 5-pillar Nov 18, 2026 | |
| Danaher (DHR) — this page | $227.56 | $160B | 71 |
| $257.84 Nov 18, 2026 | $42.5B | 71 5-pillar Nov 18, 2026 | |
| $370.78 Nov 18, 2026 | $30.1B | 71 5-pillar Nov 18, 2026 | |
| $688.75 Nov 19, 2026 | $255B | 70 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $195.00 – $275.00
- Consensus target
- $244.63
- Median target
- $250.00
Consensus record · Captured .
Measured against a quoted price of $227.56 (as of Nov 19, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Nov 9, 2026
- Transactions
- 50
- Identified insiders
- 18
- Purchases
- 0
- Sales
- 9
- Other transactions
- 41
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held DHR in their latest 13F filing, and what they did against the filing before it.
| Investor | Manager | 13F quarter | Portfolio weight | Value | Last quarter |
|---|---|---|---|---|---|
| Tiger Global | Chase Coleman | Q3 2026 | 1.39% | $281.10M | Added +178.2% shares |
| Viking Global | Andreas Halvorsen | Q3 2026 | 0.71% | $231.20M | New position |
| Bridgewater Associates | Founded by Ray Dalio | Q3 2026 | 0.38% | $87.79M | Added +1442.7% shares |
| Gates Foundation Trust | Bill & Melinda Gates Foundation | Q3 2026 | 0.28% | $82.64M | Held, unchanged |
| Third Point | Dan Loeb | Q3 2026 | 0% | $0 | Sold out (was $102.86M) |
| Duquesne Family Office | Stanley Druckenmiller | Q3 2026 | 0% | $0 | Sold out (was $9.58M) |
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Danaher (DHR)?
DHR Healthcare Stock FAQ
Research dated 2026-09-12; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
What makes Danaher’s revenue recurring?
Danaher sells reagents, consumables, software and services alongside instruments used in bioprocessing, laboratory research, clinical diagnostics and applied analysis. Those continuing purchases account for most reported revenue.
Why can Danaher’s revenue rise while operating profit falls?
In the latest period, gross profit improved only modestly from the preceding period while selling and administrative expense and research spending rose. The added operating expense more than absorbed the gross-profit increase.
Which customers drive Danaher’s Life Sciences demand?
Pharmaceutical and biopharmaceutical companies, universities, medical schools, research institutions and industrial manufacturers buy Danaher’s research instruments, genomics tools, bioprocess systems and related consumables. Their research and production activity influences both equipment purchases and continuing workflow demand.
How exposed is Danaher to debt despite its cash generation?
Debt remains well above cash and investments, despite operating cash flow consistently covering capital expenditure. That makes continued cash conversion central to preserving flexibility.
What is the DHR stock price today?
The last price recorded for Danaher Corporation (DHR), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the DHR price target?
The analyst consensus price target for Danaher Corporation (DHR), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 42 figures on this page — 1 from SEC filings and earnings calls, 35 from Financial Modeling Prep (FMP), 3 with no recorded source, 2 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources (as of 2026-09-12), by section of the research
ETFs that hold DHR
Funds in our ETF coverage that list DHR among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| FM Focus Equity ETF (FMCX) | 4.33% | |
| Madison Covered Call ETF (CVRD) | 4.18% |
